Method to Prevent HIV Infection by Maintaining APOBEC3G (A3g) in Its More Active “Low Molecular Mass” (LMM) Form

Applications:
The more active LMM form of APOBEC3G (A3g) prevents HIV from replicating within the host. Thus maintaining LMM-A3G and preventing the inactive HMM-A3G formation or preventing its degradation by the viral protein, Vif, would limit the ability of HIV to infect its host.


Advantages:
This technology provides a novel approach to increase the activity of A3G by creating molecules that facilitate the expression of the active form, LMM, or inhibiting the production of the inactive form, HMM.  These molecules would target certain protein-protein or protein-RNA interactions thus specifically prevent HMM to LMM turnover.

URV Reference Number: 6-1557
Patent Information:
Category(s):
Therapeutic
For Information, Contact:
Matan Rapoport
Licensing Associate
University of Rochester
585.276.6600
matan.rapoport@rochester.edu
Inventors:
Harold Smith
Joseph Wedekind
Keywords:
AIDS
Antiviral
HIV
RNA
Therapy